Early Multicenter Experience With Imipenem-Cilastatin-Relebactam for Multidrug-Resistant Gram-Negative Infections | Zendy

Nicholas Rebold | Zendy; Taylor Morrisette | Zendy; Abdalhamid M Lagnf | Zendy; Sara Alosaimy | Zendy; Dana Holger | Zendy; Katie E. Barber | Zendy; Julie Ann Justo | Zendy; Kayla Antosz | Zendy; Travis J Carlson | Zendy; Jeremy J Frens | Zendy; Mark Biagi | Zendy; Wesley D. Kufel | Zendy; William J Moore | Zendy; Nicholas J. Mercuro | Zendy; Brian R. Raux | Zendy; Michael J. Rybak | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Early Multicenter Experience With Imipenem-Cilastatin-Relebactam for Multidrug-Resistant Gram-Negative Infections

Author(s) -

Nicholas Rebold,

Taylor Morrisette,

Abdalhamid M Lagnf,

Sara Alosaimy,

Dana Holger,

Katie E. Barber,

Julie Ann Justo,

Kayla Antosz,

Travis J Carlson,

Jeremy J Frens,

Mark Biagi,

Wesley D. Kufel,

William J Moore,

Nicholas J. Mercuro,

Brian R. Raux,

Michael J. Rybak

Publication year - 2021

Publication title -

open forum infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.546

H-Index - 35

ISSN - 2328-8957

DOI - 10.1093/ofid/ofab554

Subject(s) - medicine , imipenem/cilastatin , imipenem , gram , gram negative bacterial infections , pathogenic organism , multiple drug resistance , cilastatin , microbiology and biotechnology , tigecycline , antibiotics , antibiotic resistance , bacteria , biology , genetics

A multicenter case series of 21 patients were treated with imipenem-cilastatin-relebactam. There were mixed infection sources, with pulmonary infections (11/21,52%) composing the majority. The primary pathogen was Pseudomonas aeruginosa (16/21, 76%), and 15/16 (94%) isolates were multidrug-resistant. Thirty-day survival occurred in 14/21 (67%) patients. Two patients experienced adverse effects.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research